{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:33:02Z","timestamp":1777660382412,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:p>A case report of a 38\u00a0years old ABO group A and Rhesus D negative multiparous, gravidae 8 and para 2, Nigerian woman who had a case of premarital miscarriage and who was not offered anti-D prophylaxis as part of her management. Lady went on to develop alloantibody D and Jka. Lady has had 7 further pregnancies post the miscarriage. The first child who is B Rhesus D positive is the only surviving child. The surviving child was delivered severely jaundiced and needed management post-delivery for haemolytic disease of the foetus and newborn (HDFN). Lady has had a history of a stillbirth. She was given a non-clinically indicated anti-D prophylaxis during the second pregnancy despite having been previously sensitized. The second baby died 3\u00a0months after delivery from complications of HDFN. She had had a further history of 5 miscarriages. She has had challenge with conception since 2010. Alloantibody testing confirms the presence alloantibody D and anti-Jka. Finding from this is a clear case of sub-optimal laboratory, obstetric and neonatal care offered particularly to pregnant women who are Rh D negative and those with alloantibodies in Nigeria. The Nigerian government will need to implement evidenced-based best practices; determination of alloantibody status of pregnant women during their first antenatal visit; provision of facilities for alloantibody identification, titration, quantification and feto maternal haemorrhage testing (FMH); implementation of a policy on universal access to anti-D prophylaxis for pregnant Rh D negative women who are not previously sensitized; provision of facilities required for the optimal intrauterine management of HDFN (foetal genotype testing, intrauterine transfusion, doppler ultrasound to diagnose anaemia inutero and provision of donor blood that meet the minimum requirements for intrauterine transfusion); determination of Rh D status of women who require a termination of pregnancy and provision of prophylactic anti-D for those found Rh D negative within 72\u00a0hours of procedure and the optimization of the knowledge of Medical Laboratory Scientist, Obstetricians, Neonatologist, Pharmacist and Traditional Birth Attendants in a bid to reduce the residual number of women who become sensitized and the number of preventable deaths of babies with HDFN.<\/jats:p>","DOI":"10.3233\/hab-200414","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:47:42Z","timestamp":1589287662000},"page":"245-252","source":"Crossref","is-referenced-by-count":2,"title":["A case report of haemolytic disease of the foetus and newborn caused by Alloantibody D and Jka in a Rhesus D negative Nigerian woman: Justification for the implementation of universal access to prophylaxis and evidenced-based best practices"],"prefix":"10.1177","volume":"28","author":[{"given":"Osaro","family":"Erhabor","sequence":"first","affiliation":[{"name":"Blood Transfusion Faculty, West African Postgraduate College of Medical Laboratory Science, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Williams Bitty","family":"Azachi","sequence":"additional","affiliation":[{"name":"Pathology Department Military Hospital Sokoto, Sokoto, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhabor","family":"Tosan","sequence":"additional","affiliation":[{"name":"Medical Laboratory Science Council of Nigeria, Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-200414_ref1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.90372"},{"key":"10.3233\/HAB-200414_ref2","first-page":"109","article-title":"Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn","volume":"13","author":"Bennardello","year":"2015","journal-title":"Blood Transfusion Trasfusione Del Sangue"},{"key":"10.3233\/HAB-200414_ref3","first-page":"237","article-title":"Recommendations for the management of haemolytic disease of the newborn","volume":"4","author":"Biffoni","year":"2006","journal-title":"Blood Transfusion"},{"key":"10.3233\/HAB-200414_ref4","doi-asserted-by":"crossref","unstructured":"D.G. Grenache, Hemolytic disease of the newborn, In: Gronowski AM, editor, Current clinical pathology: handbook of clinical testing during pregnancy. Totowa (NJ): Humana Press, 2004, pp. 219\u2013241.","DOI":"10.1007\/978-1-59259-787-1_11"},{"key":"10.3233\/HAB-200414_ref5","first-page":"600","article-title":"Management of rhesus alloimmunization in pregnancy","volume":"100","author":"Moise","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0002-9378(85)90288-1","article-title":"Controversies in Rh prophylaxis, Who needs Rh immune globulin and when should it be given","volume":"151","author":"Bowman","year":"1985","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.3233\/HAB-200414_ref9","unstructured":"J. Chilcott et al., A Review of the Clinical Effectiveness and Cost-Effectiveness of Routine Anti-D Prophylaxis for Pregnant Women Who Are Rhesus-Negative, NIHR Health Technology Assessment Programme: Executive Summaries. Southampton (UK): NIHR Journals Library, 2003."},{"key":"10.3233\/HAB-200414_ref11","first-page":"CD000021","article-title":"Anti-D administration after childbirth for preventing Rhesus alloimmunisation","volume":"2","author":"Crowther","year":"1997","journal-title":"Cochrane Database Systematic Review"},{"key":"10.3233\/HAB-200414_ref12","unstructured":"B.A. Armson et al., The Rh program of Nova Scotia 1964\u20131994. Halifax Atlantic Society of Obstetricians and Gynaecologists, 1995."},{"key":"10.3233\/HAB-200414_ref13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/jmf.10.3.175.181-9","article-title":"Etiology and outcome of hydrops fetalis","volume":"10","author":"Ismail","year":"2001","journal-title":"Journal of Maternal and Foetal Medicine"},{"key":"10.3233\/HAB-200414_ref14","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJM199812103392410","article-title":"Rh D hemolytic disease of the newborn","volume":"339","author":"Bowman","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.3233\/HAB-200414_ref15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1053\/j.seminhematol.2005.04.007","article-title":"Red blood cell alloimmunization in pregnancy","volume":"42","author":"Moise","year":"2005","journal-title":"Seminar in Hematology"},{"key":"10.3233\/HAB-200414_ref16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1054\/blre.1999.0123","article-title":"Rh D haemolytic disease of the fetus and the newborn","volume":"14","author":"Urbaniak","year":"2000","journal-title":"Blood Reviews"},{"key":"10.3233\/HAB-200414_ref17","doi-asserted-by":"crossref","first-page":"F62","DOI":"10.1136\/fn.78.1.F62","article-title":"Consequences for fetus and neonate of maternal red cell Allo-immunisation","volume":"78","author":"Howard","year":"1998","journal-title":"Archives of Disease in Childhood\u00a0\u2013 Fetal and Neonatal Edition"},{"key":"10.3233\/HAB-200414_ref18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1537-2995.2007.01625.x","article-title":"Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: A population study in the Netherlands","volume":"48","author":"Koelewijn","year":"2008","journal-title":"Transfusion"},{"key":"10.3233\/HAB-200414_ref19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.21307\/immunohematology-2019-134","article-title":"Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary care facility","volume":"29","author":"Smith","year":"2013","journal-title":"Immunohematology"},{"key":"10.3233\/HAB-200414_ref20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12288-015-0593-3","article-title":"Prevalence, specificity and titration of red cell alloantibodies in multiparous antenatal females at a tertiary care Centre from North India","volume":"32","author":"Meena","year":"2016","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"key":"10.3233\/HAB-200414_ref21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/uog.4088","article-title":"Middle cerebral artery blood flow velocities and pulsatility index and the cerebroplacental pulsatility ratio: Longitudinal reference ranges and terms for serial measurements","volume":"30","author":"Ebbing","year":"2007","journal-title":"Ultrasound in Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tjog.2019.01.008","article-title":"Fetal middle cerebral artery peak systolic velocity as a predictor of fetal anemia in unselected women giving birth at or near term","volume":"58","author":"Kawabata","year":"2019","journal-title":"Taiwanese Journal of Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref23","first-page":"e1","article-title":"Posttraumatic stress, anxiety and depression following miscarriage and ectopic pregnancy: a multicenter, prospective, cohort study","volume":"367","author":"Farren","year":"2020","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/tmrv.2003.50001","article-title":"Prenatal typing of Rh and Kell blood group system antigens: The edge of a watershed","volume":"17","author":"van der Schoot","year":"2003","journal-title":"Transfusion Medicine Reviews"},{"key":"10.3233\/HAB-200414_ref25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/pd.60","article-title":"Prenatal RHD gene determination and dosage analysis by PCR: Clinical evaluation","volume":"21","author":"Chan","year":"2001","journal-title":"Prenatal Diagnosis"},{"key":"10.3233\/HAB-200414_ref26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pd.1282","article-title":"Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies","volume":"25","author":"Hromadnikova","year":"2005","journal-title":"Prenatal Diagnosis"},{"key":"10.3233\/HAB-200414_ref27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1537-2995.2011.03362.x","article-title":"Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis","volume":"52","author":"Clausen","year":"2012","journal-title":"Transfusion"},{"key":"10.3233\/HAB-200414_ref28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1471-0528.12063","article-title":"Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation","volume":"120","author":"Lindemburg","year":"2013","journal-title":"BJOG: An International Journal of Obstetrics and Gynaecology"},{"key":"10.3233\/HAB-200414_ref30","doi-asserted-by":"crossref","first-page":"e0230073","DOI":"10.1371\/journal.pone.0230073","article-title":"Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis","volume":"15","author":"Xie","year":"2020","journal-title":"PLoS ONE"},{"key":"10.3233\/HAB-200414_ref31","doi-asserted-by":"crossref","unstructured":"M. Delaney, Haemolytic disease of the fetus and newborn: Advancements in precision and prevention, Congress Review International Society of Blood Transfusion, ISBT Science Series 14 (2019), 32\u201336.","DOI":"10.1111\/voxs.12479"},{"key":"10.3233\/HAB-200414_ref32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/tme.12091","article-title":"BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the foetus and newborn","volume":"24","author":"Qureshi","year":"2014","journal-title":"Transfusion Medicine"},{"key":"10.3233\/HAB-200414_ref33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1471-0528.1999.tb08304.x","article-title":"Routine antenatal rhesus D immunoglobulin prophylaxis: The results of a prospective 10-year study","volume":"106","author":"MacKenzie","year":"1999","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.3233\/HAB-200414_ref34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1471-0528.2004.00226.x","article-title":"The economics of routine antenatal anti-D prophylaxis for pregnant women who are Rhesus negative","volume":"111","author":"Jim","year":"2004","journal-title":"BJOG: An International Journal of Obstetrics and Gynaecology"},{"key":"10.3233\/HAB-200414_ref35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/167482b0","article-title":"A new blood group antigen","volume":"167","author":"Allen","year":"1951","journal-title":"Nature"},{"key":"10.3233\/HAB-200414_ref36","unstructured":"L. Dean, Blood Groups and Red Cell Antigens [Internet], Bethesda (MD): National Center for Biotechnology Information (US). Chapter 10, The Kidd blood group. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2272\/, 2005."},{"key":"10.3233\/HAB-200414_ref37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0029-7844(96)00434-6","article-title":"Female alloimmunization with antibodies known to cause hemolytic disease","volume":"89","author":"Geifman-Holtzman","year":"1997","journal-title":"Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0029-7844(96)00434-6","article-title":"Female alloimmunization with antibodies known to cause hemolytic disease","volume":"89","author":"Geifman-Holtzman","year":"1997","journal-title":"Obstetrics and Gynecology"},{"key":"10.3233\/HAB-200414_ref39","first-page":"144","article-title":"Severe hemolytic disease of the newborn caused by anti-Jka","volume":"4","author":"Matson","year":"1959","journal-title":"Vox Sanguine"},{"key":"10.3233\/HAB-200414_ref40","first-page":"121","article-title":"Management of anti-Jka alloimmunization","volume":"54","author":"Franco","year":"2009","journal-title":"Journal of Reproductive Medicine"},{"key":"10.3233\/HAB-200414_ref41","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1111\/jpc.12063","article-title":"Haemolytic Disease of Newborn Due to Anti-Jka and the Duration of Antibody Persistence","volume":"49","author":"Baek","year":"2013","journal-title":"Journal of Paediatric and Child Health"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-200414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:20Z","timestamp":1777447340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-200414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":38,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/hab-200414","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}